LeMaitre Vascular Inc (LMAT) delivered better-than-expected financial results for the third quarter of fiscal 2025. The company reported earnings per share (EPS) of $0.75, exceeding Wall Street's consensus estimate of $0.58 by $0.17. Revenue matched expectations at $0.1 billion, reinforcing the company’s stable financial performance.
This update provides insight into LeMaitre's operational health, particularly in the medical device sector, where it specializes in vascular devices and human tissue cryopreservation services. Headquartered in Burlington, Massachusetts, the company develops and markets products aimed at vascular surgeons and other medical specialties, including cardiac and general surgeons.
LeMaitre's portfolio includes anastomotic clips, biologic vascular and dialysis grafts, and various catheters, among others. The firm operates primarily in the United States, Europe, Canada, and Asia Pacific, employing 651 full-time staff. As of November 8, 2025, the company holds a market cap of $1,937.77 million with a P/E ratio of 41.13.
Investors are encouraged to review the full earnings release and tune into the upcoming earnings conference call for further insights into the company's performance and future outlook. The next earnings report is anticipated on August 2, 2026, with an EPS estimate of $0.6531 and revenue also estimated at $0.1 billion.